



REVA MEDICAL ANNOUNCES DEPARTURE OF RICHARD KIMES, SVP OF OPERATIONS

San Diego, California and Sydney, Australia (Thursday, 8 November 2018 - AEDT) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular medical applications, filed an 8-K with the United States Securities and Exchange Commission today stating that Richard Kimes, Senior Vice President of Operations, departed the organization on 6 November 2018 in connection with a small reduction in workforce.

Reggie Groves, Chief Executive Officer, said, “The reduction in force was implemented to ensure that we are sized appropriately for the expected slower growth in our coronary business and resourced appropriately to bring forward our nearer-term opportunities in our peripheral and embolic platforms. The revised coronary outlook is based on recently-published European Society of Cardiology guidelines related to the use of bioresorbable scaffolds, which was discussed in detail on our most recent earnings call, held on 6 November 2018. We thank Rick for all of his hard work at REVA and wish him well on his future endeavors.”

A replay of REVA’s earnings call is available on our website at www.revamedical.com.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company’s lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is currently selling Fantom in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy and Turkey. REVA is based in San Diego, California, and employs 45 people in the U.S. and Europe.

Fantom, Fantom Encore, MOTIV and Tyrocore are trademarks of REVA Medical, Inc.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that are not statements of historical fact, including those statements that address future operating plans or performance and events or developments that may occur in the future, are forward-looking statements, such as those statements regarding the Company's ability to create advancements in areas of coronary artery disease, peripheral artery disease and embolization therapies, the Company's ability to generate the clinical evidence needed to support our commercialization efforts and a modification to the ESC guidelines, the projections and timing surrounding commercial operations and sales, clinical trials, pipeline product development, and future financings. No undue reliance should be placed on forward-looking statements. Although management believes forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to vary materially from those expressed in forward-looking statements, including the risks and uncertainties that are described in the "Risk Factors" section of our Annual Report on Form 10-K filed with the US Securities and Exchange Commission (the "SEC") on March 7, 2018, and as updated in our periodic reports thereafter. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 • +1 (858) 966-3000 • +1 (858) 966-3099 (FAX) • www.revamedical.com

AUSTRALIAN OFFICE: Suite 4, Level 14, 6 O'Connell Street, Sydney NSW 2000 • +61 2 9237 2800

ARBN 146 505 777 • REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability

**United States
Investor & Media Enquiries:**
REVA Medical, Inc.
Brandi Roberts
Chief Financial Officer
+1 858-966-3003

**Australia
Investor Enquiries:**
Perpetuity Capital Pty Ltd
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

**Australia
Media Enquiries:**
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

David Schull
Russo Partners
+1 858-717-2310
david.schull@russopartnersllc.com

For personal use only